Background Controversy exists over the surgical treatment for severe patellofemoral osteoarthritis. We therefore wished to compare the outcome of patellofemoral arthroplasty (PFA) with TKA in a blinded randomized controlled trial. Questions/purposes In the first 2 years after surgery: (1) Does the overall gain in quality of life differ between the implants based on the area under the curve of patientreported outcomes (PROs) versus time? (2) Do patients obtain a better quality of life at specific points in time after PFA than after TKA? (3) Do patients get a better range of movement after PFA than after TKA? (4) Does PFA result in more complications than TKA? Methods Patients were eligible if they had debilitating symptoms and isolated patellofemoral disease. One hundred patients were included from 2007 to 2014 and were randomized to PFA or TKA (blinded for the first year; blinded to patient, therapists, primary care
overall gain in quality of life differ between the implants based on the area under the curve of patientreported outcomes (PROs) versus time? (2) Do patients obtain a better quality of life at specific points in time after PFA than after TKA? (3) Do patients get a better range of movement after PFA than after TKA? (4) Does PFA result in more complications than TKA? Methods Patients were eligible if they had debilitating symptoms and isolated patellofemoral disease. One hundred patients were included from 2007 to 2014 and were randomized to PFA or TKA (blinded for the first year; blinded to patient, therapists, primary care physicians, etc; quasiblinded to assessor). Patients were seen for four clinical followups and completed six sets of questionnaires during the first 2 postoperative years. SF-36 bodily pain was the primary outcome. Other outcomes were range of movement, PROs (SF-36, Oxford Knee Score [OKS] , Knee injury and Osteoarthritis Outcome Score [KOOS] ) as well as complications and revisions. Four percent (two of 50) of patients died within the first 2 years in the PFA group (none in the TKA group), and 2% (one of 50) became ill and declined further participation after 1 year in the PFA group (none in the TKA group). The mean age at inclusion was 64 years (SD 8.9), and 77% (77 of 100) were women. Results The area under the curve (AUC) up to 2 years for SF-36 bodily pain of patients undergoing PFA and those undergoing TKA was 9.2 (SD 4.3) and 6.5 (SD 4.5) months, respectively (p = 0.008). The SF-36 physical functioning, KOOS symptoms, and OKS also showed a better AUC up to 2 years for PFA compared with TKA (6.6 [SD 4.8] The SF-36 bodily pain improvement at 6 months for patients undergoing PFA and those undergoing TKA was 38 (SD 24) and 27 (SD 23), respectively (p = 0.041), and at 2 years, the improvement was 39 (SD 24) and 33 (SD 22) , respectively (p = 0.199). The KOOS symptoms improvement at 6 months for patients undergoing PFA and those undergoing TKA was 24 (SD 20) and 7 (SD 21), respectively (p < 0.001), and at 2 years, the improvement was 27 (SD 19) and 17 (SD 21) , respectively (p = 0.023). Improvements from baseline for KOOS pain, SF-36 physical functioning, and OKS also differed in favor of PFA at 6 months, whereas only KOOS symptoms showed a difference between the groups at 2 years. No PRO dimension showed a difference in favor of TKA. At 4 months, 1 year, and 2 years, the ROM change from baseline for patients undergoing PFA and those undergoing TKA was (-7° 
Conclusions
Patients undergoing PFA obtain a better overall kneespecific quality of life than patients undergoing TKA throughout the first 2 years after operation for isolated patellofemoral osteoarthritis. At 2 years, only KOOS function differs between patients undergoing PFA and those undergoing TKA, whereas other PRO dimensions do not show a difference between groups. The observations can be explained by patients undergoing PFA recovering faster than patients undergoing TKA and the functional outcome being better for patients undergoing PFA up to 9 months. Patients undergoing PFA regain their preoperative ROM, whereas patients undergoing TKA at 2 years have lost 10°of ROM. We found no differences in complications. Level of Evidence Level I, therapeutic study.
Introduction
P opulation studies have shown that the prevalence of isolated patellofemoral osteoarthritis (PF-OA) is between 11% and 24% in patients with knee pain who are older than 55 years of age [16, 32] , and the proportion of PF-OA in patients with degenerative knee disease seen by orthopaedic surgeons has been estimated at 2% to 5% [8, 26, 35] . TKA has been the mainstay of surgical treatment for severe PF-OA [26, 33, 35, 40] , because earlier generations of patellofemoral arthroplasty (PFA) had unpredictable results [11, 27, 48] . Newer PFA designs and strict indications may have solved earlier problems [18, 48] , and 5-year survival rates > 96% have been published [2, 39] .
However, implant registers have demonstrated poor implant survival of PFA compared with TKA [7, 13, 15, 36] . One registry has found the 10-year estimate of PFA revision to be 19% against 3% for cemented, unconstrained and fixed-bearing TKA [36] . These data have been used as arguments against PFA and unicompartmental knee arthroplasty (UKA) implants in general [9, 25, 38] . Among proponents of PFA and UKA, there is a feeling that register survival data may be misleading and unjustly limiting the use of implant types that result in better knee function [29] .
We therefore asked if the outcome of PFA and TKA differs with regard to (1) the overall gain in generic and kneespecific patient-reported quality of life; (2) patient-reported outcomes at fixed points in time; (3) the range of movement; and (4) rates of complications. We aimed to perform a double-blind (first year only) randomized controlled trial (RCT) to answer the questions. All research questions in this article are considered within a timeframe of the first 2 postoperative years.
Patients and Methods
We performed a blinded RCT between PFA and TKA with a one-to-one allocation ratio. The patients were operated on between June 2007 and October 2014. The trial was accepted by the Ethical Committee system in Denmark (ref. no. 20070025) and is recorded with ClinicalTrials.gov (ID no. NCT01326156). The current article reports on results up to 2 years only.
Patients presenting with debilitating symptoms of PF-OA in whom conservative treatment had failed, clinical examination indicated isolated PF-OA, and radiographic examination including tangential radiographs (no more than 30°flex-ion [12, 14, 20, 34] ) showed bony contact in the patellofemoral joint and preserved tibiofemoral joint lines were eligible for the trial (Fig. 1 ). There were patient-and knee-specific exclusion criteria (Table 1) . A patient with bilateral disease was eligible with both knees but could only be randomized per protocol with one knee; that is, if during the first operation the knee was found to be suitable, that knee would be randomized per protocol and the other knee would be excluded. If the first operation revealed tibiofemoral changes resulting in exclusion, the patient might still be participating with the other knee. We had three such patients. Two hundred and four knees (201 patients) were initially found eligible and 100 knees (100 patients) were randomized per protocol (Fig.  2) . The mean age for randomized patients was 64 years (SD = 8.9; range, 39-85 years), and 77% were women. Twenty-six percent of patients reported knee trouble during adolescence, 18% reported previous patella dislocation, and 2% had a history of patella fracture. Thirtyfive and 26% had previous surgery to the index and contralateral knee, respectively.
Randomization was done intraoperatively after the surgeon had ascertained that the knee would be suited for PFA. Full-thickness lesions of the tibiofemoral articular cartilage with a diameter > 6 mm led to exclusion. One hundred sealed, randomly ordered and numbered envelopes (50 PFAs and 50 TKAs) were used for randomization.
Ward nurses, therapists, physicians, and other staff were blinded to the implant. Hospital notes were modified to conceal information about the implant. The staff, except for the operating surgeon, was asked not to search for information about the implant, eg, by retrieving postoperative radiographs. Discharge letters were designed not to contain information about the implant. In some instances, notes and letters did unfortunately reveal the implant type, although this information may not have been communicated to the patient. At the 1-year appointment, patients were asked to guess their implant: of patients undergoing PFA, 19 and 18 guessed at PFA and TKA, respectively, and of patients undergoing TKA, the guesses were 13 and 25, respectively (p = 0.214); the missing answers represent uncertain patients.
Followup examinations were performed by a blinded assessor or by the surgeon who had performed the operation. Although the latter in principle was not blinded, he would usually not have any recollection of the randomization. Any trained assessor can tell the difference between TKA and PFA when testing stability. Hence, stability testing was the last part of the examination, and all study notes regarding ROM, swelling, etc, would by then have been completed. Assessors were asked not to consult radiographs until after completing the study case form. The trial was a multicenter trial. Danish orthopaedic departments were invited to participate. Inclusions could be done in any unit, but operations were performed in only five regional hospitals and in two private hospitals. The number of operations with randomization per protocol in each of the participating hospitals was 58, 26, 11, two, one, one, and one; and eight surgeons performed each 59, 13, 11, 10, three, two, one, and one operations. All participating surgeons were experienced knee surgeons. A surgeon, who might be unfamiliar with an implant, would have to be supervised during three procedures with the unfamiliar implant. The designer surgeon gave initial training in the Avon™ patellofemoral implant (Stryker Orthopaedics, Mahwah, NJ, USA); the first author (AO) then supervised the next group of surgeons.
Patients were referred by their primary care physician. At initial assessment, eligibility criteria were assessed, and if fulfilled, the trial entry form was completed. The patient was informed, and the first-year blinding was emphasized. If the patient did not decline study participation, he or she was contacted by telephone within a week, when it was assumed that he or she would have read the written information. The patient was then invited in for a second appointment at the department, where the operation would be done, the consent form was completed, the patient completed the baseline questionnaire, and the surgeon completed the preoperative form.
Postoperatively, each patient was seen for clinical followup at 2 weeks, 4 months, and 1 and 2 years. Future studies will follow these patients at 5 and 10 years. Questionnaires containing patientreported outcome measures were sent to patients at 6 weeks and 3, 6, 9, 12, and 24 months; future studies will follow them yearly (Fig. 2) . Data collection, research group and patient communication, appointment keeping, and automated supervision were performed using the Procordo system (Procordo Software, Copenhagen, Denmark).
The PFA was the Avon [1] (Howmedica, now Stryker Orthopaedics).
The instruments used were mostly the original Avon instruments, but some procedures were done with newer instruments that included a punch for outlining the contour of the trochlea. Fixation was cemented (Refobacin Bone Cement; Biomet, Warsaw, IN, USA). The surgical details of using the Avon implant can be found elsewhere [1] . The TKA was the PFC® Sigma (DePuy Synthes, Warsaw, IN, USA) in a cemented, fixed-bearing, cruciateretaining version [21] . This implant was used because it was the market leader [15] .
The assessment of the need for soft tissue realignment in both procedures was based on the position of the patella tilted to 90°. If the tilted patella could not be transposed to the midline, a synovial fold release was performed. If insufficient, peripatellar release was done. If in rare cases it was still insufficient, a midposition lateral retinacular release was performed. None of the patients required a bony realignment procedure.
All procedures were done through a midline TKA incision with medial parapatellar capsulotomy and patellar eversion when needed. The protocol stipulated the use of a tourniquet, intraarticular drain, local infiltration anesthetics [4] , and skin closure by staples. Mobilization allowing full weightbearing was started as soon as possible after surgery, and the patient was discharged when mobilizing satisfactorily and being under adequate pain control. The median length of stay for patients undergoing PFA and those undergoing TKA was 2 (range, 1-7) and 3 (range, 1-6) nights, respectively (p = 0.34).
The primary outcome was SF-36 bodily pain (version 1.0) [49] . Secondary outcomes were other patientreported outcomes [41] (Oxford Knee Score [OKS] [17] , Knee injury and • Limited range of movement (extension deficit of $ 10°or flexion < 90°)
• Complex regional pain syndrome or arthrofibrosis in case of previous procedure to ipsi-or contralateral knee Fig. 2 The study CONSORT diagram. Numbers in parentheses before the operation and randomization show the total number of knees at each step in the trial. One hundred knees in 100 patients were randomized per protocol. After operation/ randomization, the red boxes show withdrawn patients, and the numbers in parentheses denote the number of replies and clinical assessments. At the 2-year followup in the PFA arm for instance, three of 50 patients were withdrawn (one after 9 months and two after 1 year); there are 46 clinical assessments, so one patient did not attend followup. OA = osteoarthritis.
Osteoarthritis Outcome Score [KOOS] [45] , and other SF-36 [version 1.0] dimensions), results of physical examination (ROM and swelling), reoperations, and serious adverse events. The minimal clinically important difference (MCID) may be used to assess whether an observed difference between two treatment groups is likely to be perceived by the patient as important [28, 30] . The following MCIDs will be considered relevant for the patient-reported outcome (PRO) instruments used in this study. For SF-36, the MCID of physical dimensions has been found to be approximately 6 points for lower extremity conditions [5] and approximately 7 at 2 years after knee arthroplasty [19] . An MCID of 8 to 10 is generally considered valid for all KOOS dimensions [44] . The OKS has an MCID of approximately 5 [10] .
Serious adverse events (SAEs) were defined as either general (death) or knee-related (no improvement in OKS at 6 months, revision, or deep infection). It should be noted that reoperation without revision of the implant was not considered an SAE. Any SAE reasonably attributed to the study led to analyses that would have stopped inclusion in case of significant (at the 1% level) differences.
Baseline data for age, sex, body mass index, previous procedures, and clinical findings did not differ between groups. Social factors accommodation and marital status differed, and more single patients living in rented accommodations declined participation. PRO data at baseline were identical for the groups except for KOOS activities of daily living (Table 2) .
To answer our first research question, regarding overall knee-specific and generic quality of life, we compared the area under the curve for improvements from baseline in PROs. To answer the second question regarding self-assessed outcomes at individual time points, we compared paired PRO differences from baseline. The third research question regarding changes in range of movement was answered by comparing paired differences from baseline. The fourth research question regarding complications was assessed by comparing the frequency in the two randomization groups.
Statistical Analyses
The decision on sample size was based on work by Angst et al. [5] , indicating that 40 patients would be needed in each group in a two-group design aiming at demonstrating clinically meaningful differences in SF-36 bodily pain of between 7 and 8.
Paired differences between baseline and postoperative times were calculated and used for analyses whenever possible. Paired differences in PROs were normally distributed and are described by mean and SD, and differences between groups were tested using the Welch t-test. Analyses of baseline data showed that many of the PRO data were not normally distributed, and it was consequently chosen to treat baseline PRO data nonparametrically. Summary statistics are shown as median and range, and comparisons between groups were done using the Wilcoxon rank test.
We calculated the area under the curve (AUC) for PRO changes from baseline using the trapezium rule [31, 42, 46] as a measure of overall improvement in quality of life. The AUC has dimension time (months), because the x-axis has dimension time (months) and the y-axis is dimensionless (PRO measure normalized to a 0-1 scale). The AUC can be considered equivalent to the number of months with normal PRO gained or lost, and it may be converted to the average change in the PRO measure (Fig. 3) . It was chosen not to include data beyond 2 years in this article, because data beyond 2 years are incomplete. One of the 50 patients in the PFA group died between 9 and 12 months postoperatively, one patient undergoing PFA died between 12 and 24 months postoperatively, and one patient in the PFA group opted to withdraw from the study after 1 year because of concurrent illness. All patients were accounted for.
All analyses were performed using an intention-to-treat principle, which means that patients first allocated to PFA or TKA continued being analyzed as such, irrespective of revision to another component (one PFA was revised to a TKA after 14 months). The "half scale" rule for missing data was used for SF-36 and KOOS items, whereas missing data were otherwise excluded from analysis reducing the number of observations (PRO response rates at baseline; 6 weeks; and 3, 6, 9, 12, and 24 months were 98%, 94%, 98%, 94%, 95%, 98%, and 93%, respectively; clinical attendance rates at baseline, 2 weeks, 4 months, and 1 and 2 years were 100%, 94%, 97%, 97%, and 93%, respectively) (Fig. 2) . Significance was set at 5%. All SF-36 calculations were performed using QualityMetric (Lincoln, RI, USA) Health Outcomes Scoring Software Version 5.0.6163.22119. All analyses were performed using the R statistical computing and graphics environment, Version 3.2.3 [43] .
Results
Patients treated with PFA obtained a better overall knee-specific quality of life as expressed by the AUC up to 2 years. The AUC for SF-36 bodily pain was 9.2 (SD 4.3) and 6.5 months (SD 4.5) for PFA and TKA, respectively (p = 0.008). For SF-36 physical functioning, OKS, and KOOS symptoms, the AUC for PFA was also better than TKA, and all differences were between 2 and 3 months (Table 3) . We know of no data for MCID of the AUC, but the average improvement over the 2-year period was calculated from the AUC, and all differences were of a clinically important magnitude except for OKS, which was just short of the MCID of 5 ( Table 3 ). The overall effect for other SF-36 (vitality, general health, physical role, emotional role, social role, and mental health) and KOOS dimensions (pain, activities of daily living, sport and recreation, quality of life) did not differ between the groups. No PRO measure had a better AUC outcome for Fig. 3 This figure presents the AUC (areas under the curve) using the OKS for a random patient in the study. The filled circles show the changes in the OKS from a value of 14 at baseline, preoperative assessment, to 44 at 2 years. The left y-axis shows the nominal values of the OKS, and the right y-axis is normalized to a scale from 0 to 1. The dark green AUC represents the overall OKS gain that this patient achieved from the operation, and using the normalized scale, the area is 10.7 months. The AUC may be interpreted in two ways. The AUC is the same size as the area of rectangle A, where the x-dimension is the number of months with normal OKS. The AUC is also the same size as the area of rectangle B, where the y-dimension is the average OKS improvement over the observation period.
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TKA. We were interested in whether a certain range of preoperative knee symptoms resulted in a better outcome for TKA compared with PFA, and to assess this, we calculated regression lines of OKS AUC against the baseline OKS. For both TKA and PFA, the regression line had a negative slope (Fig.  4) , indicating a larger functional gain for smaller preoperative scores, but there was no range of baseline scores, in which TKA performed better than PFA. At 6 weeks and 3, 6, and 9 months, the PFA group had a better SF-36 bodily pain improvement than the TKA group (11 [SD 26] (Fig. 6) . At all time points up to and including 9 months, the SF-36 bodily pain and physical functioning dimensions showed differences between the groups of a magnitude that is clinically important (Fig. 5) . The SF-36 social role functioning and mental health dimensions showed differences at early postoperative time points, but only the social role differences were of a clinically important magnitude. The OKS differed between PFA and TKA up to 9 months (Fig. 7) , and the differences were above MCID (except at 6 weeks). The KOOS symptoms dimension differed at all time points between the groups, and all differences were above MCID. KOOS pain differed between the groups at 3 and 6 months, and the difference is above MCID. The sport/recreation and quality-of-life dimensions of the *The mean and SD are given for each PRO dimension with unit time (months); Oxford Knee Score, KOOS symptoms, SF-36 physical functioning, and SF-36 bodily pain differ significantly between the randomization groups, and differences are in favor of PFA; it may be noted that the AUC for all dimensions is larger for PFA than for TKA; the right column shows the average improvement in each of the PRO dimensions over the 2-year period (see Fig. 3 for details) ; the asterisks indicate statistical significance at the 5% level; PFA = patellofemoral arthroplasty; PRO = patient-reported outcome; KOOS = Knee injury and Osteoarthritis Outcome Score; ADL = activities of daily living; QoL = quality of life.
KOOS differed at various time points (above MCID).
Patients treated with PFA achieved a greater ROM from 4 months up to and including 2 years (Fig. 8) . The ROM at baseline for patients undergoing PFA and those undergoing TKA was 133°(SD 11°) and 132°(SD 12°), respectively (p = 0.532). Paired differences (relative to baseline) at 4 months, 1 year, and 2 years for patients undergoing PFA and those undergoing TKA were -7°(SD 13°) versus -18°( SD 14.3°) (p < 0.001); -4°(SD 15°) versus -11°(SD 12°) (p = 0.011); and -3°(11°) versus -10°(12°) (p = 0.010), respectively. There was no betweengroup difference at 2 weeks. The 2-year PFA group difference from baseline of -3°was not different from 0 (p = 0.065), whereas the 2-year TKA group difference of -10°was different from 0 (p < 0.001). There was no improvement in ROM for either group from 1 to 2 years. Similar analyses were performed for swelling and intraarticular effusion, but no between-group differences could be demonstrated.
With the numbers available, there were no differences in complications between the study groups. In the PFA arm, two patients died within 2 years after index surgery (at 11 and 18 months, death not related to the knee operation), and there were two revisions and two other subsequent procedures within 2 years. One patient undergoing PFA had no OKS improvement at 6 months and she had revision of the trochlea component at 7 months (malpositioned and proud trochlea causing patellar catching/ clicking). A second patient had persistent pain for unknown reasons and was revised to TKA at 14 months (with no improvement in pain). A patient undergoing PFA had lateral release plus medial duplication at 5 months, and a second patient undergoing PFA had an Elmslie-Trillat procedure combined with medial duplication at 24 months, both for patellar instability. There were five subsequent procedures in four patients undergoing TKA. A patient undergoing TKA had arthroscopy plus manipulation under anesthesia at 7 months and again at 14 months. Two TKAs were manipulated under anesthesia (at 2 and 4 months). A patient undergoing TKA sustained a supracondylar fracture at 5 months. Three patients undergoing TKA had no OKS improvement at 6 months.
Discussion
TKA historically has been preferred over PFA as the surgical treatment of choice for patients with severe and isolated patellofemoral arthritis [26, 33, 35, 40] , and register data have been used in support of this practice [9, 25, 38] . However, data with contemporary PFA implants suggest that it may represent a durable solution [2, 39] and perhaps one that has advantages over TKA, but to our knowledge, this has not been evaluated in a randomized trial.
Limitations
This study has several limitations. The present study reports on the 2-year Fig. 4 Area under the OKS improvement curve up to 2 years for individual patients versus baseline OKS. There is a significant negative slope (r = -0.637, p < 0.001 and r = -0.421, p = 0.007 for patients undergoing PFA and those undergoing TKA, respectively) demonstrating that patients with a lower preoperative score obtain a larger improvement. The regression lines for patients undergoing PFA and those undergoing TKA do not intersect, and PFA gives a uniformly better result than TKA.
Volume 476, Number 1results only, because data for longer followup are incomplete. If one of the groups should show unwanted results as the followup period increases, any change will have to be balanced against any advantages or disadvantages observed earlier. We find it reasonable to use the AUC (the integral) of the PROs as an overall measure of the health benefit obtained by the patient. It is difficult to achieve perfect doubleblinding in a surgical trial. However, we believe that the distribution of patients' guesses about which implant they may have had demonstrates that the patient blinding was effective. It is difficult to ascertain if the assessor blinding was effective, but we have no All surgeons participating in this study were trained in using the implants; because of this, the degree to which our results may generalize to others is uncertain, particularly if they perform PFA only sporadically. It was our intention to compare the results of the implants when used correctly for a well-defined indication, and we did not intend this study to assess the learning curve, borderline indications, or the "average surgeon" [24] . Four of the participating surgeons each performed less than five operations in this study. We performed a subgroup analysis excluding all patients operated on by these surgeons. The overall picture of study results was no different in the subgroup analysis, and only a few marginal p values changed from significant to nonsignificant or vice versa.
One should be careful not to extrapolate the findings of this study to indications other than those we applied here. We are aware that PFA is sometimes used for patients with anterior knee pain in the absence of end-stage arthritis. We would caution against this practice, because there is no documentation to support it. The radiographic criteria for inclusion in our study were preserved tibiofemoral joint lines (Kellgren-Lawrence 3-4 [23] , ; Table 1 ) and bone contact on the tangential view. Although some radiographic factors (such as the severity of the arthritis, limb alignment, or patellofemoral dysplasia) may be associated with outcomes, we do not believe they are likely to influence results within the first 2 years. We plan to evaluate them in future studies.
Isolated PF-OA primarily affects women [2, 32, 39, 48] , and in our study, women accounted for 77% of the procedures performed. A full analysis of possible gender-based differences would not only have to compare possible differences in outcome, but would also have to look for confounders (previous dislocations, history suggesting The p values below the curves are the results of t-tests of the PFA group versus the TKA group. The p values above the horizontal solid line are the results of tests of difference from the baseline ROM for the PFA and TKA groups. Two weeks after the operation, the ROM decreased approximately 50°for both groups. At later time points, the decrease in ROM was significantly larger for the TKA group. The PFA group had regained the baseline ROM by 1 year, whereas the TKA group had not regained the baseline ROM by 2 years. Error bars indicate 6 1 standard error of mean.
patellofemoral subluxation, the radiographic factors mentioned, etc). We do have all the information needed including long-leg films, but we believe that a study of this character will call for a separate paper.
Time to Recovery
The analyses of PROs were partly an analysis of the AUC and partly a complementing analysis at individual time points. The finding of differences in more patient-reported overall outcomes (SF-36 bodily pain, SF-36 physical functioning, OKS and KOOS symptoms) suggests that patients undergoing PFA gain the equivalent of 2 to 3 months of normal knee function in addition to the PRO gain that patients undergoing TKA experience.
At 2 years, only KOOS symptoms showed a difference between the groups, whereas there was no difference for other PRO dimensions. Up to 9 months, more PRO results were in favor of PFA. This together with the AUC data suggests that recovery is a few months delayed for patients undergoing TKA relative to those undergoing PFA. It appears from several of the PRO recovery curves that the maximal recovery rate (slope of the curves) is approximately equal for the implant types. The PRO values at baseline and their improvements observed in our study are of the same magnitude as those found in other knee arthroplasty studies [37, 47] .
Range of Motion
At 4 months and beyond, the PFA group had better ROM than the TKA group, but it is possible that the magnitude is too small to be clinically important (we are not aware of any MCID for ROM). At 1 year, the PFA group had regained preoperative ROM, whereas the TKA group did not regain preoperative values within the first 2 years. The pattern of changes from baseline over time in our study is similar to changes observed after medial unicompartmental arthroplasty [37] .
Complications and Reoperations
Our study has, with the present followup, not shown a higher revision rate for patients undergoing PFA than for patients undergoing TKA. One may over time expect revisions for progression of disease in the PFA group. If this happens, the temporary loss of function related to revision will have to be balanced by the functional advantage associated with the primary PFA. There have been only a few complications in both treatment groups, and there is no statistical difference in the numbers. In early studies, very high reoperation rates for patellofemoral instability and patella tracking problems were noted [11, 48] , but we have not seen this as a problem. Patient populations and implant designs may differ, but it is likely that indications, surgical experience, and focus on soft tissue realignment procedures as described for the Avon implant [1] can prevent most problems. These factors are uncontrolled in register studies.
All published register data have to our knowledge shown the revision rate of PFA to be much higher than TKA [7, 13, 15, 36] , and this is often taken as an argument not to use PFA [6, 9] . We believe that register data, although complete and valid, are confounded and biased, and the common interpretation of register results is misleading when comparing two different implant types like PFA and TKA.
Conclusions
Based on the 2-year results of our blinded randomized study, we suggest that PFA rather than TKA should be performed in cases of debilitating isolated PF-OA. Patients undergoing PFA enjoy a higher knee-related quality of life and range of movement than patients undergoing TKA during the first 2 postoperative years. The results challenge register data, and if the results remain favorable over longer term followup, they should result in a shift in implant selection from TKA to PFA in patients with isolated patellofemoral arthritis.
